

Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation

NCT06430021

Status RECRUITING
Sponsor Centre Hospitalier Universitaire Dijon
Enrollment 297 participants

Key Eligibility Criteria

Inclusion (9)

- Patients with proven MEN1, symptomatic or not, confirmed on the basis of the following international criteria (Thakker et al.):
 - patients with an MEN1 mutation;
 - patients belonging to an identified MEN1 family in which at least one first-degree relative has been affected and has at least one MEN1-related lesion;
 - patients without a positive genetic test or a family history of the disease, but with at least two of the three main MEN1 lesions (parathyroid adenomas, duodenopancreatic NETs and pituitary tumours).
 - Majors patients,
- ... and 4 more (see full listing online)

Exclusion (3)

- Person not affiliated to national health insurance
- Person subject to a measure legal protection (curatorship, guardianship, family empowerment) or a court order
- Pregnant, parturient or breastfeeding mothers

Locations (1 total)

Chu Dijon Bourgogne, Dijon, France